dupilumab asthma
Selected indexed studies
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. (N Engl J Med, 2018) [PMID:29782217]
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. (N Engl J Med, 2021) [PMID:34879449]
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (J Allergy Clin Immunol, 2023) [PMID:36538979]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (2023) pubmed
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. (2020) pubmed
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. (2018) pubmed
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. (2021) pubmed
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. (2018) pubmed
- Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study. (2025) pubmed
- Dupilumab for the treatment of asthma. (2017) pubmed
- Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. (2022) pubmed
- A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. (2024) pubmed
- Dupilumab in persistent asthma with elevated eosinophil levels. (2013) pubmed